Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
New Clinical Data Raise Questions About GLP-1 Therapy and Bone Density The Structural Side of GLP-1 Weight Loss New research presented yesterday at the AAOS Annual Meeting has shifted part of the GLP-1 conversation from weight loss to skeletal health
In this retrospective cohort study of electronic health records (EHRs) from the TriNetX Analytics Network, a global federated health research network of approximately 105.3 million patients from 61 large healthcare organizations in the US, we aimed to assess the associations of semaglutide with both incident and recurrent CUD diagnosis compared to non-GLP-1RA anti-obesity or anti-diabetes medications
The discovery of these pathways has made it possible to affect Th17/Treg cell-associated diseases by manipulating or targeting the regulation of Gln metabolism (56)
Future research with dedicated, long-term clinical trials is needed to determine their potential as disease-modifying therapies in DN
Importantly, these biochemical changes were not accompanied by behavioral recovery
- Segment focus SWOT Merck and Co
US$ 24.24
US$ 21.55
US$ 28.93
US$ 22.17
US$ 21.55
